Abstract
In addition to being a novel medication in treating obesity and type 2 diabetes mellitus, tirzepatide is currently being studied to assess its effectiveness and safety on various health parameters, specifically with an emphasis on the neurological field, including sleep medicine and neurodegenerative conditions. In this perspective, we highlight the recent FDA approval of tirzepatide’s use for the treatment of obstructive sleep apnea, with recommendations for future research to extend use in children and adolescents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
No datasets were generated or analyzed during the perspective.
Code Availability
Not applicable.
References
Al-Ameri LT, Hameed EK, Dulaimi Z, Abdalgbar A, Wahdan MY, Al Joboory A, et al. A revolutionary road map for obesity management and beyond: tirzepatide as a dual-acting insulinotropic polypeptide. Al-Kindy Col Med J. 2024;20(3):158–62. https://doi.org/10.47723/hesy7z38.
U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea, Zepbound (Tirzepatide). FDA News Release. 2024 Dec 20. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea?utm_source=chatgpt.com.
Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193–205. https://doi.org/10.1056/NEJMoa2404881.
Eli Lilly and Company. Efficacy and safety study of tirzepatide in adolescents with obesity or overweight. Clinical Trials. 2023. Available from: https://trials.lilly.com/en-US/trial/427361. Accessed 20 Jan 2025.
Baylor College of Medicine. Phase 1 study of tirzepatide for childhood obesity treatment. Clinical Trials. 2023. Available from: https://www.bcm.edu/healthcare/clinical-trials/h-53214. Accessed 20 Jan 2025.
Author information
Authors and Affiliations
Contributions
LTA, HA, and EKH wrote the main manuscript text, reviewed, edited, and approved the final content of this Comment.
Corresponding author
Ethics declarations
Ethics Approval
Not applicable.
Consent to Participate
Not applicable.
Consent for Publication
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Al-Ameri, L.T., Al-Momen, H. & Hameed, E.K. A New Pharmacological Direction in Sleep Medicine: Tirzepatide’s FDA Approval for Obstructive Sleep Apnea. SN Compr. Clin. Med. 7, 333 (2025). https://doi.org/10.1007/s42399-025-02111-y
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s42399-025-02111-y